Blood pressure and cardiovascular effects of new and emerging antidiabetic agents

Pelbreton C. Balfour, Carlos J. Rodriguez, Keith C. Ferdinand

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Despite remarkable declines in US cardiovascular disease morbidity and mortality over the last several decades, the prevalence of risk factors such as type 2 diabetes and hypertension remains high, associated with increasing obesity rates. Although optimal glycemic control remains a primary focus to decrease the disease burden, the FDA has issued guidance recommendations for documenting cardiovascular disease-related safety with research trials on new antidiabetic agents with more demanding requirements compared to past approval of existing therapies. This review will discuss the public health impact of type 2 diabetes, specifically with comorbid hypertension; mechanisms of action of the newest antidiabetic drug classes; and preliminary findings and potential clinical significance of the favorable blood pressure and body weight effects of the sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists; and additionally discuss two recent large cardiovascular outcome trials with dipeptidyl peptidase-4 inhibitors.

Original languageEnglish (US)
Article number455
JournalCurrent Hypertension Reports
Volume16
Issue number8
DOIs
Publication statusPublished - Aug 2014

    Fingerprint

Keywords

  • Antidiabetic drugs
  • Cardiovascular disease
  • Diabetes
  • Dipeptidyl peptidase-4 inhibitors
  • Glucagon-like peptide-1 receptor agonists
  • Hypertension
  • Obesity
  • Sodium-glucose cotransporter 2 inhibitors
  • Systolic blood pressure

ASJC Scopus subject areas

  • Internal Medicine

Cite this